T. Rowe Price Associates’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-33,977
| Closed | -$307K | – | 3192 |
|
|
2025
Q4 | $307K | Sell |
33,977
-35,100
| -51% | -$262K | ﹤0.01% | 2632 |
|
|
2025
Q3 | $215K | Hold |
69,077
| – | – | ﹤0.01% | 2767 |
|
|
2025
Q2 | $148K | Sell |
69,077
-26,609
| -28% | -$43K | ﹤0.01% | 2811 |
|
|
2025
Q1 | $111K | Buy |
95,686
+54,400
| +132% | +$93.4K | ﹤0.01% | 2799 |
|
|
2024
Q4 | $91K | Sell |
41,286
-13,616
| -25% | -$30.9K | ﹤0.01% | 2848 |
|
|
2024
Q3 | $120K | Buy |
54,902
+2,169
| +4% | +$4.99K | ﹤0.01% | 2786 |
|
|
2024
Q2 | $122K | Buy |
52,733
+4,706
| +10% | +$19.6K | ﹤0.01% | 2718 |
|
|
2024
Q1 | $265K | Sell |
48,027
-155,291
| -76% | -$710K | ﹤0.01% | 2489 |
|
|
2023
Q4 | $503K | Sell |
203,318
-3,623,237
| -95% | -$34.4M | ﹤0.01% | 2166 |
|
|
2023
Q3 | $133M | Sell |
3,826,555
-122,738
| -3% | -$4.24M | 0.02% | 461 |
|
|
2023
Q2 | $130M | Buy |
3,949,293
+1,263,761
| +47% | +$43.6M | 0.02% | 480 |
|
|
2023
Q1 | $90M | Buy |
2,685,532
+879,958
| +49% | +$34.2M | 0.01% | 533 |
|
|
2022
Q4 | $59.2M | Buy |
1,805,574
+1,120,232
| +163% | +$33.2M | 0.01% | 626 |
|
|
2022
Q3 | $23.9M | Buy |
+685,342
| New | +$15.2M | ﹤0.01% | 856 |
|
Other funds holding VTYX
T. Rowe Price Associates's VTYX Position: Q1 2026 in Review
T. Rowe Price Associates sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 33,977 shares — an estimated $307K sold.
T. Rowe Price Associates first reported a position in VTYX in Q3 2022 and held it in 14 quarters. The position peaked at $133M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- T. Rowe Price Associates reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- T. Rowe Price Associates sold 33,977 Ventyx Biosciences shares in Q1 2026, an estimated $307K.
- T. Rowe Price Associates first reported a position in Ventyx Biosciences in Q3 2022 and held it in 14 quarters.
- T. Rowe Price Associates's Ventyx Biosciences position peaked at $133M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.